Skip to Content

    Funded Studies Details

    Funded Studies Details

    << Back

     

    2022 Pilot Awards for Global Brain Health Leaders (GBHI)

    Economic Evaluation of Support Monitoring and Reminder Technology for People with Cognitive Impairment and Their Caregivers

    How cost-effective is a novel smart technology app for monitoring health and promoting care in individuals at risk of dementia?

    Sanjib Saha, Ph.D.
    Lund University
    Lund, Sweden



    Background

    As dementia becomes more prevalent worldwide, researchers are looking for novel, cost-effective ways of improving care practices for individuals with cognitive (brain function) decline and their caregivers. Such methods have, in recent years, often involved smart technology. One recent study tested a novel app called the Support, Monitoring and Reminder Technology for Mild Dementia (SMART4MD). This tablet app is designed to promote the care of individuals at risk of dementia through digital reminders of health care appointments, games that stimulate cognitive function and other features. From 2017 to 2020, SMART4MD was tested in two European countries — Spain and Sweden — by individuals with mild cognitive impairment (MCI, a condition of subtle memory loss that may precede dementia) and their caregivers. More than 1,000 caregiver/care recipient teams participated, some of whom received the SMART4MD therapy and some who received standard care.   

    Research Plan

    As dementia becomes more prevalent worldwide, researchers are looking for novel, cost-effective ways of improving care practices for individuals with cognitive (brain function) decline and their caregivers. Such methods have, in recent years, often involved smart technology. One recent study tested a novel app called the Support, Monitoring and Reminder Technology for Mild Dementia (SMART4MD). This tablet app is designed to promote the care of individuals at risk of dementia through digital reminders of health care appointments, games that stimulate cognitive function and other features. From 2017 to 2020, SMART4MD was tested in two European countries — Spain and Sweden — by individuals with mild cognitive impairment (MCI, a condition of subtle memory loss that may precede dementia) and their caregivers. More than 1,000 caregiver/care recipient teams participated, some of whom received the SMART4MD therapy and some who received standard care.   

    Impact

    This study could help determine the viability of a novel technology-based tool for improving dementia care. It could also lead to larger studies assessing the economic impact of similar technologies. 

    The first survivor of Alzheimer's is out there, but we won't get there without you.

    Donate Now

    Learn how Alzheimer’s disease affects the brain.

    Take the Brain Tour

    Don't just hope for a cure. Help us find one.

    Learn More